We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic Drugmakers, Biotechs Settle on Substitution Rules for Biosimilars
Generic Drugmakers, Biotechs Settle on Substitution Rules for Biosimilars
Generic drugmakers and the biotech industry have drafted a set of rules to govern when and how biosimilars can be substituted for brand-name biologics.